Can carbetocin be administered to a woman with preeclampsia for prevention of postpartum hemorrhage?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Carbetocin Can Be Safely Given in Preeclampsia

Yes, carbetocin can be administered to women with preeclampsia for prevention of postpartum hemorrhage, and emerging evidence suggests it may actually be preferable to oxytocin in this population due to its more favorable hemodynamic profile.

Evidence from Guidelines

The most recent 2026 Enhanced Recovery After Surgery (ERAS) guidelines identify carbetocin as "probably the most effective agent" for preventing postpartum hemorrhage, noting it is recommended as a first-line uterotonic where available (though not currently available in the US) 1. Importantly, these guidelines do not list preeclampsia as a contraindication to carbetocin use.

The 2018 International Society for the Study of Hypertension in Pregnancy (ISSHP) guidelines extensively address management of preeclampsia but do not specifically contraindicate carbetocin 2. The guidelines emphasize careful hemodynamic management in preeclamptic patients, noting they require "even greater hemodynamic care and attention" with focus on achieving euvolemia 1.

Critical Distinction: Drug Label Confusion

The FDA drug labels provided 3 are for carboplatin (a chemotherapy agent), NOT carbetocin (the uterotonic). This is a completely different medication and should be disregarded for this question.

Research Evidence Supporting Use in Preeclampsia

Multiple high-quality studies directly address carbetocin use in preeclamptic patients:

Efficacy and Safety Studies

  • 2023 randomized controlled trial 4: Compared carbetocin versus oxytocin in preeclamptic patients undergoing cesarean section under spinal anesthesia. Carbetocin demonstrated significantly better hemodynamic stability with less increase in heart rate, smaller decline in blood pressure, and better oxygen saturation compared to oxytocin. Fewer patients required additional uterotonic doses with carbetocin (3 cases) versus oxytocin (7 cases).

  • 2011 double-blind RCT 5: Specifically studied 60 women with severe preeclampsia, comparing carbetocin to oxytocin. Found carbetocin was "as effective as oxytocin" with a "safety profile similar to that of oxytocin" and importantly, was not associated with development of oliguria or hypertension in this cohort.

  • 2016 before-after cohort study 6: Examined 60 women with severe preeclampsia undergoing cesarean delivery. Found carbetocin "as effective and safe as oxytocin in preeclamptic women," with similar rates of additional uterotonic use (15% vs 10%, p=0.70).

Clinical Reasoning

Why Carbetocin May Be Superior in Preeclampsia

  1. Hemodynamic stability: Preeclamptic patients have capillary leak, altered cardiac output, and are at risk for pulmonary edema 1, 2. Carbetocin's more stable hemodynamic profile with less hypotension and tachycardia is advantageous 4.

  2. Single-dose administration: Carbetocin requires only one injection versus oxytocin infusion over hours, reducing fluid administration in patients who need strict fluid restriction (60-80 mL/h recommended) 2.

  3. Longer duration of action: The 4-10 times longer half-life means sustained uterotonic effect without repeated dosing 7.

  4. No increased hypertension risk: Despite theoretical concerns, studies show carbetocin does not cause problematic hypertension in preeclamptic patients 5, 4.

Important Caveats

  • Historical contraindication: One 2009 review noted that "preeclampsia is still a contraindication to the administration of carbetocin in the EU" and called for further cardiovascular studies 7. However, subsequent research from 2011-2023 has directly addressed this concern and demonstrated safety 5, 6, 4.

  • Timing consideration: One study suggested reserving carbetocin until after placental delivery due to increased retention rates in general population 8, though this was not specifically studied in preeclamptic patients.

  • Availability: Carbetocin is not available in the United States 1.

Practical Recommendation

For preeclamptic patients requiring uterotonic prophylaxis, carbetocin is an appropriate and potentially superior alternative to oxytocin. The evidence demonstrates equivalent efficacy with potentially better hemodynamic tolerability—a critical consideration in this high-risk population already prone to cardiovascular complications. Where carbetocin is available, it should be considered the preferred first-line uterotonic in women with preeclampsia, particularly those with severe features or cardiovascular instability.

References

Research

Carbetocin versus oxytocin for prevention of postpartum hemorrhage in patients with severe preeclampsia: a double-blind randomized controlled trial.

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2011

Research

Prevention of postpartum haemorrhage with the oxytocin analogue carbetocin.

European journal of obstetrics, gynecology, and reproductive biology, 2009

Research

Carbetocin for the prevention of post-partum hemorrhage after vaginal birth: a real-world application.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.